Az antilipidaemiás kezelés szerepe idült vesebetegségben

Translated title of the contribution: The role of antilipidaemic therapy in chronic kidney disease

Research output: Contribution to journalReview article

Abstract

In chronic kidney disease (CKD), the risk of cardiovascular mortality is remarkably high, which is partly due to lipid alterations. The results with statin treatment in cardiovascular prevention studies and in CKD, and their metaanalysis show that antilipidaemic therapy decreases overall and cardiovascular mortality in the predialysed state. On the basis of the new study SHARP, coadministration of simvastatin plus ezetimib also significantly reduces the number of atherosclerotic events in predialysed CKD (this was the first positive hard-endpoint result regarding the combination), thus it can be considered as an alternative. A large-scale metaanalysis of two earlier studies assessing the dialysed patients and patients of the SHARP study who received only dialysis indicated that antilipidaemic therapy was successful, as the number of nonfatal myocardial infarctions and coronary revascularisation interventions have been significantly reduced. These new results also show that in patients who need dialysis, the efficiency of statin or statin plus ezetimib therapy is decreased compared to predialysed state - owing to the partly different pathomechanism-, but this antilipidaemic therapy - especially in those with a high cardiovascular risk - can reduce the incidence of cardiovascular events.

Original languageHungarian
Pages (from-to)89-93
Number of pages5
JournalLege Artis Medicinae
Volume22
Issue number2
Publication statusPublished - Feb 1 2012

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this